BIOMARK PROVIDES BUSINESS UPDATE AND SECOND QUARTER Financial RESULTS
BIOMARK PROVIDES BUSINESS UPDATE AND SECOND QUARTER Financial RESULTS Vancouver, British Columbia – (November 28, 2022) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to reports that it will amend the […]
BIOMARK’s GLIOBLASTOMA Study Published in CANCERS Demonstrates Inhibiting SAT1 sensitized cancer cells towards radiation and chemotherapy
BIOMARK’s GLIOBLASTOMA Study Published in CANCERS Demonstrates Inhibiting SAT1 Sensitized Cancer Cells Towards Radiation and Chemotherapy Vancouver, British Columbia – (October 27th, 2022) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today […]
The US Patent Office Grants BIOMARK Additional Patent for its LIQUID BIOPSY Technology
THE US PATENT OFFICE GRANTS BIOMARK ADDITIONAL PATENT FOR ITS LIQUID BIOPSY TECHNOLOGY Vancouver, British Columbia – (September 20, 2022) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that the US […]
BioMark TO PRESENT VALIDATION DATA OF ITS Multianalyte Metabolite Panel for Lung Cancer Screening at THE ESMO CONGRESS 2022
BioMark TO PRESENT VALIDATION DATA OF ITS Multianalyte Metabolite Panel for Lung Cancer Screening at THE ESMO CONGRESS 2022 Vancouver, British Columbia – (September 8, 2022) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased […]
BIOMARK SELECTED BY the Medical Alley and Investissement Quebec TO JOIN the US Go-to-Market Accelerator
BIOMARK SELECTED BY THE MEDICAL ALLEY AND INVESTISSEMENT QUEBEC TO JOIN THE US GO-TO-MARKET ACCELERATOR Vancouver, British Columbia – (September 1, 2022) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an oncology-focused company with advanced near-to-market liquid biopsy diagnostic technologies is pleased to announce today that its Quebec-based wholly-owned subsidiary BioMark Diagnostic […]
BioMark provides First Quarter 2022 Financial Results and Operational Update
BIOMARK PROVIDES FIRST-QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL UPDATE Vancouver, British Columbia – (August 30, 2022) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an oncology-focused company with advanced near-to-market liquid biopsy diagnostic technologies announced today its financial results and operational update for the quarter ended June 30, 2022. […]
BIOMARK PROVIDES Financial Results FOR THE YEAR ENDED MARCH 31, 2022, and Recent Corporate Highlights
BIOMARK PROVIDES FINANCIAL RESULTS FOR THE YEAR ENDED MARCH 31, 2022, AND RECENT CORPORATE HIGHLIGHTS Vancouver, British Columbia – (July 14, 2022) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an oncology-focused company with advanced near-to-market liquid biopsy diagnostic technologies is pleased to announce today its financial results and […]
Form 7 Monthly Progress Report – July 2022
Form 7 – Monthly CSE Progress Report June 2022 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 83,286,229 August 2nd, 2022 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not […]
Press Release – BioMark Continues to Strengthen its Intellectual Property position With New Patent
and Trademark Use in Canada
BioMark Continues to Strengthen its Intellectual Property position With New Patent and Trademark Use in Canada Vancouver, British Columbia – (June 21st, 2022) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company developing molecular diagnostic tests with a focus on hard to detect and […]
BioTech Brothers Interview with Rashid Ahmed CEO BioMark Diagnostics
